Exscientia
-
Milton Park companies secure over 7% of UK’s life sciences equity investment
New research commissioned by Milton Park reveals that £2.14 billion of equity investment was generated across 272 companies based in the science, technology and business community over the past decade.
-
Exscientia selects Milton Park for new laboratories
The expansion will see the firm occupy 20,151sq ft of laboratory and office space at 155 Brook Drive, which is part of the Science Vale Enterprise Zone.
-
Exscientia expands headquarters at The Oxford Science Park
The company, which initially occupied c7,800 sq ft in the Schrödinger Building is increasing capacity for its technology teams by expanding to 21,000 sq ft of facilities.
-
Exscientia acquires personalised medicine AI pioneer Allcyte
The combination expands Exscientia’s capabilities by enabling high content evaluation of individual patient biology in primary tumour tissues rather than artificial cell lines or animal models.
-
Exscientia announces first AI-designed immuno-oncology drug in clinical trials
The company’s technologies and drug-hunting expertise now responsible for the world’s first and second AI-designed drugs to enter Phase I testing.